ClinicalTrials.gg
CompletedNCT02888704Updated Dec 22, 2017

Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis

A Phase 1 interventional study of ADSTEM Inj. (Adult human mesenchymal stem cells) in Atopic Dermatitis, sponsored by EHL Bio Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-12-22.

Sponsored by EHL Bio Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Dermatitis, Atopic with a site in Korea, Republic of — 7 open to participants now, 18 under way, 7 of them phase 3. Dermatitis, Atopic · Korea, Republic of.

Enrollment
71st of 71
13 · median 234
Started
2016
with 6 others
Phase 1
4 of 83
none open now
Registered
16th of 83
by date
Lead sponsor
4 of 83
EHL Bio Co., Ltd.

Among the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of, this one is the 71st largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2016, is one of 4 in phase 1, and was the 16th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

7 of the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Dermatitis, Atopic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to evaluate safety, tolerance, and efficacy in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of autologous mesenchymal stem cells. The study is composed of two steps. Step 1 is to determine clinically proper dose capacity of the ADSTEM Inj. and step 2 is to evaluate exploratory efficacy of the ADSTEM Inj. at the proper dose.

Read the detailed description

Atopic dermatitis (AD) is a type of inflammation of the skin. It results in itchy, swollen, red, and cracked skin. The symptoms typically start in childhood with changing severity over the years. The pathogenesis of AD is characterized by excessive type 2 helper T cell mediated inflammatory responses, resulting in B lymphocyte mediated increase in serum level of immunoglobulin E (IgE). Subsequent degranulation of mast cells by IgE releases various inflammatory mediators, which recruit the lymphocytes and eosinophils into the lesion.

Current clinical management of AD includes topical corticosteroids and systemic immunosuppressants. However, these drugs have been reported to carry the risk of side-effects and severe.

Several recent studies including ours have demonstrated that mesenchymal stem cells (MSCs) could suppress allergic responses in AD. MSCs have been known to interact with cell types of both innate and adaptive immune systems, which results in the suppressive effect on proliferation, differentiation, and activation of immune cells including T cells, B cells, dendritic cells, and natural killer cells. Indeed, a number of studies have reported that the immunomodulatory ability of MSCs can be usefully applied for the treatment of autoimmune and inflammation-related diseases such as asthma, rhinitis, and dermatitis. Therefore, MSCs has possibility as a new drug for AD.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic dermatitis
  • Mesenchymal stem cells
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Of either gender, aged ≥19 and ≤70 years
  • Atopic dermatitis subjects who are coincident with Hanifin and Rajka diagnosis criteria
  • Subacute and chronic atopic subjects who have atopic dermatitis symptoms continually at least 6 months
  • Subjects with over moderate atopic dermatitis (SCORAD score > 20)
  • Subjects who understand and voluntarily sign an form

Exclusion criteria

Exclusion Criteria:

  • Subjects who have systemic infection
  • Subjects who have (HIV), virus (HBV), and virus (HCV)
  • Subjects who need to take the medicine which is prohibited during this study
  • Subjects who have asthma
  • Subjects who can not stop treatment with topical (group 1\~5), oral antibiotics, whole body photochemotherapy, drug within 4 weeks before the treatment visit
  • Pregnant, breast-feeding women or women who plan to become pregnant during this study (Females of must have a negative urine pregnancy test)
  • Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days
  • Subjects who had a serious adverse events during stem cell therapy
  • Subjects who had a to antibiotics or antimycotics
  • Subjects who creatinine value is more than two times of the at screening test
  • Subjects who /alkaline transaminase (AST/ALT) value is more than three times of the upper limit of the normal range at screening test
  • Subjects who have any other condition which the investigator judges would make patients unsuitable for study participation
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    intervention: Biological: ADSTEM Inj.

    1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study. 2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.

    Drug: ADSTEM Inj. (Adult human mesenchymal stem cells)

Interventions

  • DrugADSTEM Inj. (Adult human mesenchymal stem cells)

    Comparison of different dosages of the drug in the aspect of safety and efficacy.

    Also known as: ADSTEM Inj.

06

What researchers measure

Primary outcomes

  1. The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03

    physical exam, vital sign, laboratory findings, and adverse drug reactions

    Time frame: 12 weeks follow-up after treatment

Secondary outcomes

  1. The reduction ratio of scoring atopic dermatitis (SCORAD) index as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  2. The variation of SCORAD index as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  3. The variation of each index score of SCORAD index as contrasted with baseline value

    TBSA, erythema, edema/papulation, oozing/crusting, excoriation, lichenification, dryness, pruritus, and insomnia

    Time frame: 12 weeks follow-up after treatment

  4. The variation of the degrees of disease as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  5. The variation of investigator's global assessment (IGA) as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  6. The variation of eczema area and severity index (EASI) total score as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  7. The variation of total immunoglobulin E (IgE) in serum as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  8. The variation of total prostaglandin E2 (PGE2) in serum as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  9. The variation of total eosinophil cationic protein (ECP) in serum as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  10. The variation of total Chemokine ligand 17 (CCL17) in serum as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

  11. The variation of total Chemokine ligand 27 (CCL27) in serum as contrasted with baseline value

    Time frame: 12 weeks follow-up after treatment

07

Study locations

1 site
  • Chungnam National University Hospital
    Daejeon, Chungcheongnam-do 35015, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2016
First posted
Sep 5, 2016
Start
Jul 2016
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Last update
Dec 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02888704
Lead sponsor
EHL Bio Co., Ltd.
Responsible party
Sponsor
First posted
Sep 5, 2016
Start date
Jul 2016
Primary completion
Dec 2017
Completion
Dec 2017
Last update
Dec 22, 2017

Study contacts

Young-joon Seo, M.D., Ph.D
principal investigator · Chungnam National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion